Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatments for Bruxism-Related Temporomandibular Disorder Symptoms
NCT07586072Phase 4Completed
- Sponsor
- Recep Tayyip Erdoğan University
- Start
- Aug 2024
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Nucleic Acid-Directed Small Molecules, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of botulinum toxin type A, thiocolchicoside, tenoxicam in temporomandibular disorders (TMD), bruxism, myofascial pain syndrome (MPS), sponsored by Recep Tayyip Erdoğan University. Started Aug 2024; status: completed.
02
Drugs
botulinum toxin type Athiocolchicosidetenoxicam
03
Conditions
temporomandibular disorders (TMD)bruxismmyofascial pain syndrome (MPS)
Beyond the preview
Go deeper on NCT07586072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07586072.